- Home
- OBIO vs CTNM Comparison
OBIO vs CTNM Comparison
Compare OBIO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- CTNM
- Stock Information
- Founded
- OBIO 2017
- CTNM 2009
- Country
- OBIO United States
- CTNM United States
- Employees
- OBIO N/A
- CTNM N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- CTNM
- Sector
- OBIO Health Care
- CTNM
- Exchange
- OBIO Nasdaq
- CTNM Nasdaq
- Market Cap
- OBIO 124.9M
- CTNM 122.9M
- IPO Year
- OBIO N/A
- CTNM 2024
- Fundamental
- Price
- OBIO $3.01
- CTNM $4.76
- Analyst Decision
- OBIO Strong Buy
- CTNM Strong Buy
- Analyst Count
- OBIO 5
- CTNM 4
- Target Price
- OBIO $14.20
- CTNM $22.50
- AVG Volume (30 Days)
- OBIO 236.8K
- CTNM 119.1K
- Earning Date
- OBIO 08-11-2025
- CTNM 08-12-2025
- Dividend Yield
- OBIO N/A
- CTNM N/A
- EPS Growth
- OBIO N/A
- CTNM N/A
- EPS
- OBIO N/A
- CTNM N/A
- Revenue
- OBIO $2,886,000.00
- CTNM N/A
- Revenue This Year
- OBIO $20.47
- CTNM N/A
- Revenue Next Year
- OBIO $11.45
- CTNM N/A
- P/E Ratio
- OBIO N/A
- CTNM N/A
- Revenue Growth
- OBIO 30.23
- CTNM N/A
- 52 Week Low
- OBIO $2.37
- CTNM $3.35
- 52 Week High
- OBIO $8.87
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- OBIO 47.82
- CTNM N/A
- Support Level
- OBIO $2.91
- CTNM N/A
- Resistance Level
- OBIO $3.48
- CTNM N/A
- Average True Range (ATR)
- OBIO 0.26
- CTNM 0.00
- MACD
- OBIO -0.01
- CTNM 0.00
- Stochastic Oscillator
- OBIO 28.78
- CTNM 0.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.